The Mesothelioma Treatment Center at the Baylor College of Medicine Lung Institute is looking for malignant pleural mesothelioma patients to try a new treatment that combines immunotherapy with a new drug that accelerates cell death.
A cancer immunotherapy research group at Baylor College of Medicine has secured Investigational New Drug regulatory clearance through the FDA to perform phase I clinical studies in newly-diagnosed adult patients with glioblastoma.
Gliogene, a study that aims to identify hereditary links of glioma, a rare and deadly form of brain cancer, has begun recruiting families affected by the disease in order to identify genes that contribute to its onset and inform susceptibility.
In a new study, ethics scholar Dr. Stephanie Morain explores a trend of oncology trial recruitment via mobile apps, and what these app companies and consumers need to consider in terms of privacy and data protection
Analyzing both the entire set of genes and all the proteins produced by colon cancer tissues from patient samples has revealed a more comprehensive view of the tumor that points at novel cancer biological mechanisms and possible new therapeutic strategies.